PubMed:19759529 / 230-462 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T3","span":{"begin":0,"end":232},"obj":"Sentence"}],"text":"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor."}

{"project":"LitCoin-entities-OrganismTaxon-PD","denotations":[{"id":"T3","span":{"begin":135,"end":141},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":157,"end":161},"obj":"OrganismTaxon"}],"attributes":[{"id":"A3","pred":"db_id","subj":"T3","obj":"NCBItxid:9605"},{"id":"A4","pred":"db_id","subj":"T4","obj":"NCBItxid:76236"}],"text":"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor."}

{"project":"LitCoin-entities","denotations":[{"id":"6452","span":{"begin":49,"end":95},"obj":"GeneOrGeneProduct"},{"id":"6453","span":{"begin":104,"end":117},"obj":"DiseaseOrPhenotypicFeature"},{"id":"6454","span":{"begin":135,"end":141},"obj":"OrganismTaxon"},{"id":"6455","span":{"begin":218,"end":231},"obj":"GeneOrGeneProduct"}],"attributes":[{"id":"A6","pred":"db_id","subj":"6452","obj":"NCBIGene:14810"},{"id":"A7","pred":"db_id","subj":"6453","obj":"MESH:D012559"},{"id":"A8","pred":"db_id","subj":"6454","obj":"NCBITaxon:9606"},{"id":"A9","pred":"db_id","subj":"6455","obj":"NCBIGene:14810"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T6","span":{"begin":30,"end":44},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":49,"end":58},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":70,"end":79},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":81,"end":85},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":87,"end":95},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":118,"end":122},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":218,"end":231},"obj":"GeneOrGeneProduct"}],"text":"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T4","span":{"begin":30,"end":44},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":49,"end":58},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":70,"end":79},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":81,"end":85},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":87,"end":95},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":118,"end":122},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":218,"end":231},"obj":"GeneOrGeneProduct"}],"text":"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T2","span":{"begin":104,"end":117},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A2","pred":"originalLabel","subj":"T2","obj":"DISEASE"}],"text":"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T2","span":{"begin":30,"end":44},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":49,"end":58},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":80,"end":95},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":218,"end":231},"obj":"GeneOrGeneProduct"}],"text":"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T2","span":{"begin":104,"end":117},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A2","pred":"ID:","subj":"T2","obj":"DISEASE"}],"text":"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T2","span":{"begin":104,"end":117},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A2","pred":"#label","subj":"T2","obj":"DISEASE"}],"text":"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T8","span":{"begin":49,"end":58},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":59,"end":79},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":81,"end":85},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":218,"end":222},"obj":"ChemicalEntity"}],"attributes":[{"id":"A8","pred":"ID:","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_29987"},{"id":"A9","pred":"ID:","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_14321"},{"id":"A10","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A11","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_6121"},{"id":"A12","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A13","pred":"ID:","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_6121"},{"id":"A14","pred":"ID:","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"}],"text":"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T2","span":{"begin":135,"end":141},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":157,"end":161},"obj":"OrganismTaxon"}],"text":"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T13","span":{"begin":218,"end":222},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":81,"end":85},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":59,"end":79},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":49,"end":58},"obj":"ChemicalEntity"},{"id":"T61861","span":{"begin":218,"end":231},"obj":"GeneOrGeneProduct"},{"id":"T43077","span":{"begin":80,"end":95},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":49,"end":58},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":30,"end":44},"obj":"GeneOrGeneProduct"},{"id":"T42836","span":{"begin":104,"end":117},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T92123","span":{"begin":157,"end":161},"obj":"OrganismTaxon"},{"id":"T77100","span":{"begin":135,"end":141},"obj":"OrganismTaxon"}],"attributes":[{"id":"A14","pred":"ID:","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A13","pred":"ID:","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_6121"},{"id":"A12","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A11","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_6121"},{"id":"A10","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A9","pred":"ID:","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_14321"},{"id":"A8","pred":"ID:","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_29987"},{"id":"A56944","pred":"#label","subj":"T42836","obj":"DISEASE"}],"text":"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor."}

{"project":"Allie","denotations":[{"id":"SS1_19759529_2_0","span":{"begin":59,"end":79},"obj":"expanded"},{"id":"SS2_19759529_2_0","span":{"begin":81,"end":85},"obj":"abbr"}],"relations":[{"id":"AE1_19759529_2_0","pred":"abbreviatedTo","subj":"SS1_19759529_2_0","obj":"SS2_19759529_2_0"}],"text":"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor."}